Evidence map›Paper›PMID 37106396›Full record

ReviewJournal of translational medicine2023

Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis.

M R Openshaw, E Gervasi, C A M Fulgenzi, D J Pinato, A Dalla Pria, M Bower

Open access · goldAbstract readReview
In one paragraph

Review in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

M R OpenshawInstitute of Cancer and Genomics Sciences, University of Birmingham, Birmingham, UK. mropenshaw@doctors.org.uk.ORCID 0000-0001-6973-3067
E GervasiInfectious Diseases Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy.
C A M FulgenziDepartment of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, UK.
D J PinatoDepartment of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, UK.
A Dalla PriaUK National Centre for HIV Oncology, Chelsea Westminster Hospital, London, UK.
M BowerUK National Centre for HIV Oncology, Chelsea Westminster Hospital, London, UK.
Chelsea and Westminster Hospital · GBCancer Research UK Clinical Trials Unit · GBOspedale Papa Giovanni XXIII · ITUniversità Campus Bio-Medico · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundThe taxonomy of Kaposi Sarcoma (KS) is based on a classification system focused on the description of clinicopathological features of KS in geographically and clinically diverse populations. The classification includes classic, endemic, epidemic/HIV associated and iatrogenic KS, and KS in men who have sex with men (MSM). We assessed the medical relevance of the current classification of KS and sought clinically useful improvements in KS taxonomy.

methodsWe reviewed the demographic and clinicopathological features of 676 patients with KS, who were referred to the national centre for HIV oncology at Chelsea Westminster hospital between 2000 and 2021.

resultsDemographic differences between the different subtypes of KS exist as tautological findings of the current classification system. However, no definitive differences in clinicopathological, virological or immunological parameters at presentation could be demonstrated between the classic, endemic or MSM KS patients. Reclassifying patients as either immunosuppressed or non-immunosuppressed, showed that the immunosuppressed group had a significantly higher proportion of adverse disease features at presentation including visceral disease and extensive oral involvement, classified together as advanced disease (chi

conclusionThe current system of KS classification does not reflect meaningful differences in clinicopathological presentation or disease pathogenesis. Reclassification of patients based on the presence or absence of immunosuppression is a more clinically meaningful system that may influence therapeutic approaches to KS.

Indexed as

HIV InfectionsSarcoma, KaposiSexual and Gender MinoritiesCD4 Lymphocyte CountHomosexuality, MaleHumansMaleAcquired immune deficiency syndromeDisease classificationHuman herpes virus 8Human immunodeficiency virusKaposi Sarcoma

Identifiers

PMID37106396
PMCPMC10142155
OpenAlexW4367320727

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.